Current scientific evidence
Scientific rigor in R&D
The miRoncol Real-time Multi-Cancer Early Risk Assessment model was studied rigorously based on large sets of cancer patients and healthy controls . Results demonstrate high accuracy across multiple solid tumour types, providing meaningful early insight that complements physician-led care with peer reviewed publications
Why Accuracy Matters
For an early risk assessment tool to be valuable, it must:
- Detect biological signals reliably, even at early stages of cancer development
- Minimize false positives, ensuring confidence for both individuals and physicians
- Work across multiple common cancers, not just one or two types
miRoncol has been designed and validated with these principles at its core.
Scientific study overview
- 11,000+ samples analyzed across 13 cancer types*
- 4,000+ healthy control samples included in studied
- Specificity: 99.3% (meaning very few healthy individuals were misclassified)
- Sensitivity: >90% for 9 major cancers; 75–85% for several others
- Tissue of Origin Accuracy: 95% for identifying the likely organ site in positive cases
*Our current test does not detect Breast cancer accurately. People with breast cancer can still get a positive signal. The sensitivity is not as high as other common solid tumors we have studied.
Cancer Types Studied
Studies included cancers that represent the majority of cases seen in Canada and worldwide, including:
- Lung
- Colorectal
- Prostate
- Pancreatic
- Gastric
- Ovarian
- Liver & biliary tract
- Bladder
- Sarcoma
- Glioma
Peer-Reviewed Publications
The scientific foundation of miRoncol’s test has been published in respected journals:
- Cancers (2022): Describing a novel blood-based microRNA diagnostic model for multi-cancer detection.
- Scientific Reports (2024): Presenting real-world studies of blood-based multi-cancer detection using microRNAs.
Limitations & Ethics
While accuracy is high, no test is perfect, and results should always be interpreted with care. A positive result signals that certain molecular patterns have been detected it does not mean cancer is present, but rather that follow-up with your physician may be helpful.
Likewise, a negative result means no cancer-linked patterns were detected at this time, but it does not replace conventional screenings or ongoing prevention. The test is designed to add meaningful, real-time insight that complements existing medical evaluations.
Next Step
miRoncol is currenting conducting studies before launching the first version of its test in 2026 Canada wide.
Join the Waiting List
Be among the first to access real-time multi-cancer risk assessment for your health and prevention plan.
Download Publications
Read the peer-reviewed research behind miRoncol’s innovative approach.
Partner With Us
Be among the first clinics to bring real-time multi-cancer risk assessment to your patients and set a new standard in preventive care.
Employer Program
Stay ahead in employee wellness by offering cutting-edge cancer risk assessment as part of your health and benefits strategy.
